Market Analysis and Insights: Global Selective Cox-2 Inhibitors Market
The research report studies the Selective Cox-2 Inhibitors market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Selective Cox-2 Inhibitors market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
Global Selective Cox-2 Inhibitors Scope and Segment
The global Selective Cox-2 Inhibitors market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Selective Cox-2 Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
by Type, the market is primarily split into
Meloxicam
Celecoxib
Etoricoxib
Imrecoxib
Etodolac
Parecoxib
Other
by Application, this report covers the following segments
Rheumatoid Arthritis
Osteoarthritis
Spondylosis Chronica Ankylopoietica
Other
Global Selective Cox-2 Inhibitors market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Selective Cox-2 Inhibitors key players in this market include:
Boehringer-Ingelheim
TerSera Therapeutics
Iroko Pharmaceuticals
Apotex
Yung Shin Pharmaceutical
Breckenridge Pharmaceutical
Meda Pharmaceuticals
Cipla
Glenmark Pharmaceuticals
Teva
PuraCap Pharmaceutical
Almirall Limited
Lupin Pharmaceuticals
Aurobindo Pharma
Pfizer
Mylan
Takeda
Bayer
Novacap
Abbott
Geri-Care
Perrigo
Kopran
Merck
Hengrui pharmaceutical
Kelun Group
Qilu Pharmaceutical
Taro Pharmaceuticals
The research report studies the Selective Cox-2 Inhibitors market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Selective Cox-2 Inhibitors market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
Global Selective Cox-2 Inhibitors Scope and Segment
The global Selective Cox-2 Inhibitors market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Selective Cox-2 Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
by Type, the market is primarily split into
Meloxicam
Celecoxib
Etoricoxib
Imrecoxib
Etodolac
Parecoxib
Other
by Application, this report covers the following segments
Rheumatoid Arthritis
Osteoarthritis
Spondylosis Chronica Ankylopoietica
Other
Global Selective Cox-2 Inhibitors market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Selective Cox-2 Inhibitors key players in this market include:
Boehringer-Ingelheim
TerSera Therapeutics
Iroko Pharmaceuticals
Apotex
Yung Shin Pharmaceutical
Breckenridge Pharmaceutical
Meda Pharmaceuticals
Cipla
Glenmark Pharmaceuticals
Teva
PuraCap Pharmaceutical
Almirall Limited
Lupin Pharmaceuticals
Aurobindo Pharma
Pfizer
Mylan
Takeda
Bayer
Novacap
Abbott
Geri-Care
Perrigo
Kopran
Merck
Hengrui pharmaceutical
Kelun Group
Qilu Pharmaceutical
Taro Pharmaceuticals
1 Market Overview of Selective Cox-2 Inhibitors
1.1 Selective Cox-2 Inhibitors Market Overview
1.1.1 Selective Cox-2 Inhibitors Product Scope
1.1.2 Selective Cox-2 Inhibitors Market Status and Outlook
1.2 Global Selective Cox-2 Inhibitors Market Size Overview by Region 2016 VS 2021VS 2027
1.3 Global Selective Cox-2 Inhibitors Market Size by Region (2016-2027)
1.4 Global Selective Cox-2 Inhibitors Historic Market Size by Region (2016-2021)
1.5 Global Selective Cox-2 Inhibitors Market Size Forecast by Region (2022-2027)
1.6 Key Regions, Selective Cox-2 Inhibitors Market Size (2016-2027)
1.6.1 North America Selective Cox-2 Inhibitors Market Size (2016-2027)
1.6.2 Europe Selective Cox-2 Inhibitors Market Size (2016-2027)
1.6.3 Asia-Pacific Selective Cox-2 Inhibitors Market Size (2016-2027)
1.6.4 Latin America Selective Cox-2 Inhibitors Market Size (2016-2027)
1.6.5 Middle East & Africa Selective Cox-2 Inhibitors Market Size (2016-2027)
2 Selective Cox-2 Inhibitors Market Overview by Type
2.1 Global Selective Cox-2 Inhibitors Market Size by Type: 2016 VS 2021 VS 2027
2.2 Global Selective Cox-2 Inhibitors Historic Market Size by Type (2016-2021)
2.3 Global Selective Cox-2 Inhibitors Forecasted Market Size by Type (2022-2027)
2.4 Meloxicam
2.5 Celecoxib
2.6 Etoricoxib
2.7 Imrecoxib
2.8 Etodolac
2.9 Parecoxib
2.10 Other
3 Selective Cox-2 Inhibitors Market Overview by Application
3.1 Global Selective Cox-2 Inhibitors Market Size by Application: 2016 VS 2021 VS 2027
3.2 Global Selective Cox-2 Inhibitors Historic Market Size by Application (2016-2021)
3.3 Global Selective Cox-2 Inhibitors Forecasted Market Size by Application (2022-2027)
3.4 Rheumatoid Arthritis
3.5 Osteoarthritis
3.6 Spondylosis Chronica Ankylopoietica
3.7 Other
4 Selective Cox-2 Inhibitors Competition Analysis by Players
4.1 Global Selective Cox-2 Inhibitors Market Size by Players (2016-2021)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Selective Cox-2 Inhibitors as of 2020)
4.3 Date of Key Players Enter into Selective Cox-2 Inhibitors Market
4.4 Global Top Players Selective Cox-2 Inhibitors Headquarters and Area Served
4.5 Key Players Selective Cox-2 Inhibitors Product Solution and Service
4.6 Competitive Status
4.6.1 Selective Cox-2 Inhibitors Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Boehringer-Ingelheim
5.1.1 Boehringer-Ingelheim Profile
5.1.2 Boehringer-Ingelheim Main Business
5.1.3 Boehringer-Ingelheim Selective Cox-2 Inhibitors Products, Services and Solutions
5.1.4 Boehringer-Ingelheim Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.1.5 Boehringer-Ingelheim Recent Developments
5.2 TerSera Therapeutics
5.2.1 TerSera Therapeutics Profile
5.2.2 TerSera Therapeutics Main Business
5.2.3 TerSera Therapeutics Selective Cox-2 Inhibitors Products, Services and Solutions
5.2.4 TerSera Therapeutics Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.2.5 TerSera Therapeutics Recent Developments
5.3 Iroko Pharmaceuticals
5.5.1 Iroko Pharmaceuticals Profile
5.3.2 Iroko Pharmaceuticals Main Business
5.3.3 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Products, Services and Solutions
5.3.4 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.3.5 Apotex Recent Developments
5.4 Apotex
5.4.1 Apotex Profile
5.4.2 Apotex Main Business
5.4.3 Apotex Selective Cox-2 Inhibitors Products, Services and Solutions
5.4.4 Apotex Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.4.5 Apotex Recent Developments
5.5 Yung Shin Pharmaceutical
5.5.1 Yung Shin Pharmaceutical Profile
5.5.2 Yung Shin Pharmaceutical Main Business
5.5.3 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Products, Services and Solutions
5.5.4 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.5.5 Yung Shin Pharmaceutical Recent Developments
5.6 Breckenridge Pharmaceutical
5.6.1 Breckenridge Pharmaceutical Profile
5.6.2 Breckenridge Pharmaceutical Main Business
5.6.3 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Products, Services and Solutions
5.6.4 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.6.5 Breckenridge Pharmaceutical Recent Developments
5.7 Meda Pharmaceuticals
5.7.1 Meda Pharmaceuticals Profile
5.7.2 Meda Pharmaceuticals Main Business
5.7.3 Meda Pharmaceuticals Selective Cox-2 Inhibitors Products, Services and Solutions
5.7.4 Meda Pharmaceuticals Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.7.5 Meda Pharmaceuticals Recent Developments
5.8 Cipla
5.8.1 Cipla Profile
5.8.2 Cipla Main Business
5.8.3 Cipla Selective Cox-2 Inhibitors Products, Services and Solutions
5.8.4 Cipla Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.8.5 Cipla Recent Developments
5.9 Glenmark Pharmaceuticals
5.9.1 Glenmark Pharmaceuticals Profile
5.9.2 Glenmark Pharmaceuticals Main Business
5.9.3 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Products, Services and Solutions
5.9.4 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.9.5 Glenmark Pharmaceuticals Recent Developments
5.10 Teva
5.10.1 Teva Profile
5.10.2 Teva Main Business
5.10.3 Teva Selective Cox-2 Inhibitors Products, Services and Solutions
5.10.4 Teva Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.10.5 Teva Recent Developments
5.11 PuraCap Pharmaceutical
5.11.1 PuraCap Pharmaceutical Profile
5.11.2 PuraCap Pharmaceutical Main Business
5.11.3 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Products, Services and Solutions
5.11.4 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.11.5 PuraCap Pharmaceutical Recent Developments
5.12 Almirall Limited
5.12.1 Almirall Limited Profile
5.12.2 Almirall Limited Main Business
5.12.3 Almirall Limited Selective Cox-2 Inhibitors Products, Services and Solutions
5.12.4 Almirall Limited Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.12.5 Almirall Limited Recent Developments
5.13 Lupin Pharmaceuticals
5.13.1 Lupin Pharmaceuticals Profile
5.13.2 Lupin Pharmaceuticals Main Business
5.13.3 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Products, Services and Solutions
5.13.4 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.13.5 Lupin Pharmaceuticals Recent Developments
5.14 Aurobindo Pharma
5.14.1 Aurobindo Pharma Profile
5.14.2 Aurobindo Pharma Main Business
5.14.3 Aurobindo Pharma Selective Cox-2 Inhibitors Products, Services and Solutions
5.14.4 Aurobindo Pharma Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.14.5 Aurobindo Pharma Recent Developments
5.15 Pfizer
5.15.1 Pfizer Profile
5.15.2 Pfizer Main Business
5.15.3 Pfizer Selective Cox-2 Inhibitors Products, Services and Solutions
5.15.4 Pfizer Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.15.5 Pfizer Recent Developments
5.16 Mylan
5.16.1 Mylan Profile
5.16.2 Mylan Main Business
5.16.3 Mylan Selective Cox-2 Inhibitors Products, Services and Solutions
5.16.4 Mylan Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.16.5 Mylan Recent Developments
5.17 Takeda
5.17.1 Takeda Profile
5.17.2 Takeda Main Business
5.17.3 Takeda Selective Cox-2 Inhibitors Products, Services and Solutions
5.17.4 Takeda Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.17.5 Takeda Recent Developments
5.18 Bayer
5.18.1 Bayer Profile
5.18.2 Bayer Main Business
5.18.3 Bayer Selective Cox-2 Inhibitors Products, Services and Solutions
5.18.4 Bayer Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.18.5 Bayer Recent Developments
5.19 Novacap
5.19.1 Novacap Profile
5.19.2 Novacap Main Business
5.19.3 Novacap Selective Cox-2 Inhibitors Products, Services and Solutions
5.19.4 Novacap Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.19.5 Novacap Recent Developments
5.20 Abbott
5.20.1 Abbott Profile
5.20.2 Abbott Main Business
5.20.3 Abbott Selective Cox-2 Inhibitors Products, Services and Solutions
5.20.4 Abbott Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.20.5 Abbott Recent Developments
5.21 Geri-Care
5.21.1 Geri-Care Profile
5.21.2 Geri-Care Main Business
5.21.3 Geri-Care Selective Cox-2 Inhibitors Products, Services and Solutions
5.21.4 Geri-Care Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.21.5 Geri-Care Recent Developments
5.22 Perrigo
5.22.1 Perrigo Profile
5.22.2 Perrigo Main Business
5.22.3 Perrigo Selective Cox-2 Inhibitors Products, Services and Solutions
5.22.4 Perrigo Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.22.5 Perrigo Recent Developments
5.23 Kopran
5.23.1 Kopran Profile
5.23.2 Kopran Main Business
5.23.3 Kopran Selective Cox-2 Inhibitors Products, Services and Solutions
5.23.4 Kopran Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.23.5 Kopran Recent Developments
5.24 Merck
5.24.1 Merck Profile
5.24.2 Merck Main Business
5.24.3 Merck Selective Cox-2 Inhibitors Products, Services and Solutions
5.24.4 Merck Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.24.5 Merck Recent Developments
5.25 Hengrui pharmaceutical
5.25.1 Hengrui pharmaceutical Profile
5.25.2 Hengrui pharmaceutical Main Business
5.25.3 Hengrui pharmaceutical Selective Cox-2 Inhibitors Products, Services and Solutions
5.25.4 Hengrui pharmaceutical Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.25.5 Hengrui pharmaceutical Recent Developments
5.26 Kelun Group
5.26.1 Kelun Group Profile
5.26.2 Kelun Group Main Business
5.26.3 Kelun Group Selective Cox-2 Inhibitors Products, Services and Solutions
5.26.4 Kelun Group Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.26.5 Kelun Group Recent Developments
5.27 Qilu Pharmaceutical
5.27.1 Qilu Pharmaceutical Profile
5.27.2 Qilu Pharmaceutical Main Business
5.27.3 Qilu Pharmaceutical Selective Cox-2 Inhibitors Products, Services and Solutions
5.27.4 Qilu Pharmaceutical Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.27.5 Qilu Pharmaceutical Recent Developments
5.28 Taro Pharmaceuticals
5.28.1 Taro Pharmaceuticals Profile
5.28.2 Taro Pharmaceuticals Main Business
5.28.3 Taro Pharmaceuticals Selective Cox-2 Inhibitors Products, Services and Solutions
5.28.4 Taro Pharmaceuticals Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.28.5 Taro Pharmaceuticals Recent Developments
6 North America
6.1 North America Selective Cox-2 Inhibitors Market Size by Country (2016-2027)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Selective Cox-2 Inhibitors Market Size by Country (2016-2027)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Region (2016-2027)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Selective Cox-2 Inhibitors Market Size by Country (2016-2027)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Country (2016-2027)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Selective Cox-2 Inhibitors Market Dynamics
11.1 Selective Cox-2 Inhibitors Industry Trends
11.2 Selective Cox-2 Inhibitors Market Drivers
11.3 Selective Cox-2 Inhibitors Market Challenges
11.4 Selective Cox-2 Inhibitors Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
1.1 Selective Cox-2 Inhibitors Market Overview
1.1.1 Selective Cox-2 Inhibitors Product Scope
1.1.2 Selective Cox-2 Inhibitors Market Status and Outlook
1.2 Global Selective Cox-2 Inhibitors Market Size Overview by Region 2016 VS 2021VS 2027
1.3 Global Selective Cox-2 Inhibitors Market Size by Region (2016-2027)
1.4 Global Selective Cox-2 Inhibitors Historic Market Size by Region (2016-2021)
1.5 Global Selective Cox-2 Inhibitors Market Size Forecast by Region (2022-2027)
1.6 Key Regions, Selective Cox-2 Inhibitors Market Size (2016-2027)
1.6.1 North America Selective Cox-2 Inhibitors Market Size (2016-2027)
1.6.2 Europe Selective Cox-2 Inhibitors Market Size (2016-2027)
1.6.3 Asia-Pacific Selective Cox-2 Inhibitors Market Size (2016-2027)
1.6.4 Latin America Selective Cox-2 Inhibitors Market Size (2016-2027)
1.6.5 Middle East & Africa Selective Cox-2 Inhibitors Market Size (2016-2027)
2 Selective Cox-2 Inhibitors Market Overview by Type
2.1 Global Selective Cox-2 Inhibitors Market Size by Type: 2016 VS 2021 VS 2027
2.2 Global Selective Cox-2 Inhibitors Historic Market Size by Type (2016-2021)
2.3 Global Selective Cox-2 Inhibitors Forecasted Market Size by Type (2022-2027)
2.4 Meloxicam
2.5 Celecoxib
2.6 Etoricoxib
2.7 Imrecoxib
2.8 Etodolac
2.9 Parecoxib
2.10 Other
3 Selective Cox-2 Inhibitors Market Overview by Application
3.1 Global Selective Cox-2 Inhibitors Market Size by Application: 2016 VS 2021 VS 2027
3.2 Global Selective Cox-2 Inhibitors Historic Market Size by Application (2016-2021)
3.3 Global Selective Cox-2 Inhibitors Forecasted Market Size by Application (2022-2027)
3.4 Rheumatoid Arthritis
3.5 Osteoarthritis
3.6 Spondylosis Chronica Ankylopoietica
3.7 Other
4 Selective Cox-2 Inhibitors Competition Analysis by Players
4.1 Global Selective Cox-2 Inhibitors Market Size by Players (2016-2021)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Selective Cox-2 Inhibitors as of 2020)
4.3 Date of Key Players Enter into Selective Cox-2 Inhibitors Market
4.4 Global Top Players Selective Cox-2 Inhibitors Headquarters and Area Served
4.5 Key Players Selective Cox-2 Inhibitors Product Solution and Service
4.6 Competitive Status
4.6.1 Selective Cox-2 Inhibitors Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Boehringer-Ingelheim
5.1.1 Boehringer-Ingelheim Profile
5.1.2 Boehringer-Ingelheim Main Business
5.1.3 Boehringer-Ingelheim Selective Cox-2 Inhibitors Products, Services and Solutions
5.1.4 Boehringer-Ingelheim Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.1.5 Boehringer-Ingelheim Recent Developments
5.2 TerSera Therapeutics
5.2.1 TerSera Therapeutics Profile
5.2.2 TerSera Therapeutics Main Business
5.2.3 TerSera Therapeutics Selective Cox-2 Inhibitors Products, Services and Solutions
5.2.4 TerSera Therapeutics Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.2.5 TerSera Therapeutics Recent Developments
5.3 Iroko Pharmaceuticals
5.5.1 Iroko Pharmaceuticals Profile
5.3.2 Iroko Pharmaceuticals Main Business
5.3.3 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Products, Services and Solutions
5.3.4 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.3.5 Apotex Recent Developments
5.4 Apotex
5.4.1 Apotex Profile
5.4.2 Apotex Main Business
5.4.3 Apotex Selective Cox-2 Inhibitors Products, Services and Solutions
5.4.4 Apotex Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.4.5 Apotex Recent Developments
5.5 Yung Shin Pharmaceutical
5.5.1 Yung Shin Pharmaceutical Profile
5.5.2 Yung Shin Pharmaceutical Main Business
5.5.3 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Products, Services and Solutions
5.5.4 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.5.5 Yung Shin Pharmaceutical Recent Developments
5.6 Breckenridge Pharmaceutical
5.6.1 Breckenridge Pharmaceutical Profile
5.6.2 Breckenridge Pharmaceutical Main Business
5.6.3 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Products, Services and Solutions
5.6.4 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.6.5 Breckenridge Pharmaceutical Recent Developments
5.7 Meda Pharmaceuticals
5.7.1 Meda Pharmaceuticals Profile
5.7.2 Meda Pharmaceuticals Main Business
5.7.3 Meda Pharmaceuticals Selective Cox-2 Inhibitors Products, Services and Solutions
5.7.4 Meda Pharmaceuticals Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.7.5 Meda Pharmaceuticals Recent Developments
5.8 Cipla
5.8.1 Cipla Profile
5.8.2 Cipla Main Business
5.8.3 Cipla Selective Cox-2 Inhibitors Products, Services and Solutions
5.8.4 Cipla Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.8.5 Cipla Recent Developments
5.9 Glenmark Pharmaceuticals
5.9.1 Glenmark Pharmaceuticals Profile
5.9.2 Glenmark Pharmaceuticals Main Business
5.9.3 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Products, Services and Solutions
5.9.4 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.9.5 Glenmark Pharmaceuticals Recent Developments
5.10 Teva
5.10.1 Teva Profile
5.10.2 Teva Main Business
5.10.3 Teva Selective Cox-2 Inhibitors Products, Services and Solutions
5.10.4 Teva Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.10.5 Teva Recent Developments
5.11 PuraCap Pharmaceutical
5.11.1 PuraCap Pharmaceutical Profile
5.11.2 PuraCap Pharmaceutical Main Business
5.11.3 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Products, Services and Solutions
5.11.4 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.11.5 PuraCap Pharmaceutical Recent Developments
5.12 Almirall Limited
5.12.1 Almirall Limited Profile
5.12.2 Almirall Limited Main Business
5.12.3 Almirall Limited Selective Cox-2 Inhibitors Products, Services and Solutions
5.12.4 Almirall Limited Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.12.5 Almirall Limited Recent Developments
5.13 Lupin Pharmaceuticals
5.13.1 Lupin Pharmaceuticals Profile
5.13.2 Lupin Pharmaceuticals Main Business
5.13.3 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Products, Services and Solutions
5.13.4 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.13.5 Lupin Pharmaceuticals Recent Developments
5.14 Aurobindo Pharma
5.14.1 Aurobindo Pharma Profile
5.14.2 Aurobindo Pharma Main Business
5.14.3 Aurobindo Pharma Selective Cox-2 Inhibitors Products, Services and Solutions
5.14.4 Aurobindo Pharma Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.14.5 Aurobindo Pharma Recent Developments
5.15 Pfizer
5.15.1 Pfizer Profile
5.15.2 Pfizer Main Business
5.15.3 Pfizer Selective Cox-2 Inhibitors Products, Services and Solutions
5.15.4 Pfizer Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.15.5 Pfizer Recent Developments
5.16 Mylan
5.16.1 Mylan Profile
5.16.2 Mylan Main Business
5.16.3 Mylan Selective Cox-2 Inhibitors Products, Services and Solutions
5.16.4 Mylan Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.16.5 Mylan Recent Developments
5.17 Takeda
5.17.1 Takeda Profile
5.17.2 Takeda Main Business
5.17.3 Takeda Selective Cox-2 Inhibitors Products, Services and Solutions
5.17.4 Takeda Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.17.5 Takeda Recent Developments
5.18 Bayer
5.18.1 Bayer Profile
5.18.2 Bayer Main Business
5.18.3 Bayer Selective Cox-2 Inhibitors Products, Services and Solutions
5.18.4 Bayer Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.18.5 Bayer Recent Developments
5.19 Novacap
5.19.1 Novacap Profile
5.19.2 Novacap Main Business
5.19.3 Novacap Selective Cox-2 Inhibitors Products, Services and Solutions
5.19.4 Novacap Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.19.5 Novacap Recent Developments
5.20 Abbott
5.20.1 Abbott Profile
5.20.2 Abbott Main Business
5.20.3 Abbott Selective Cox-2 Inhibitors Products, Services and Solutions
5.20.4 Abbott Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.20.5 Abbott Recent Developments
5.21 Geri-Care
5.21.1 Geri-Care Profile
5.21.2 Geri-Care Main Business
5.21.3 Geri-Care Selective Cox-2 Inhibitors Products, Services and Solutions
5.21.4 Geri-Care Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.21.5 Geri-Care Recent Developments
5.22 Perrigo
5.22.1 Perrigo Profile
5.22.2 Perrigo Main Business
5.22.3 Perrigo Selective Cox-2 Inhibitors Products, Services and Solutions
5.22.4 Perrigo Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.22.5 Perrigo Recent Developments
5.23 Kopran
5.23.1 Kopran Profile
5.23.2 Kopran Main Business
5.23.3 Kopran Selective Cox-2 Inhibitors Products, Services and Solutions
5.23.4 Kopran Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.23.5 Kopran Recent Developments
5.24 Merck
5.24.1 Merck Profile
5.24.2 Merck Main Business
5.24.3 Merck Selective Cox-2 Inhibitors Products, Services and Solutions
5.24.4 Merck Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.24.5 Merck Recent Developments
5.25 Hengrui pharmaceutical
5.25.1 Hengrui pharmaceutical Profile
5.25.2 Hengrui pharmaceutical Main Business
5.25.3 Hengrui pharmaceutical Selective Cox-2 Inhibitors Products, Services and Solutions
5.25.4 Hengrui pharmaceutical Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.25.5 Hengrui pharmaceutical Recent Developments
5.26 Kelun Group
5.26.1 Kelun Group Profile
5.26.2 Kelun Group Main Business
5.26.3 Kelun Group Selective Cox-2 Inhibitors Products, Services and Solutions
5.26.4 Kelun Group Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.26.5 Kelun Group Recent Developments
5.27 Qilu Pharmaceutical
5.27.1 Qilu Pharmaceutical Profile
5.27.2 Qilu Pharmaceutical Main Business
5.27.3 Qilu Pharmaceutical Selective Cox-2 Inhibitors Products, Services and Solutions
5.27.4 Qilu Pharmaceutical Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.27.5 Qilu Pharmaceutical Recent Developments
5.28 Taro Pharmaceuticals
5.28.1 Taro Pharmaceuticals Profile
5.28.2 Taro Pharmaceuticals Main Business
5.28.3 Taro Pharmaceuticals Selective Cox-2 Inhibitors Products, Services and Solutions
5.28.4 Taro Pharmaceuticals Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021)
5.28.5 Taro Pharmaceuticals Recent Developments
6 North America
6.1 North America Selective Cox-2 Inhibitors Market Size by Country (2016-2027)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Selective Cox-2 Inhibitors Market Size by Country (2016-2027)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Region (2016-2027)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Selective Cox-2 Inhibitors Market Size by Country (2016-2027)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Country (2016-2027)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Selective Cox-2 Inhibitors Market Dynamics
11.1 Selective Cox-2 Inhibitors Industry Trends
11.2 Selective Cox-2 Inhibitors Market Drivers
11.3 Selective Cox-2 Inhibitors Market Challenges
11.4 Selective Cox-2 Inhibitors Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
